HUMAGRIP 16 TABLETS

You're reading an Auto-translation.

Composition.

Active substances are:

Tablet: paracetamol 500 mg, pseudoephedrine hydrochloride 60 mg

Capsule: paracetamol 500 mg, chlorpheniramine maleate 4 mg.

Other components are:

Tablet: microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, povidone K 30.

Capsule: talc, sodium lauryl sulfate, anhydrous colloidal silicon dioxide, croscarmellose sodium, erythrosine (E127), indigotine (E132), titanium dioxide (E171), gelatin.

Therapeutic indications.

HUMAGRIP tablets and capsules is a systemic nasal decongestant, sympathomimetic, peripheral analgesic, antipyretic and H1 antihistamine.

HUMAGRIP tablets and capsules is indicated for the short-term symptomatic treatment of flu-like conditions accompanied by headache and/or fever and a "stuffy nose" sensation.

It is recommended only for adults and children over 15 years of age. If after 4 days you do not feel better or feel worse, you should consult a doctor.

Dosage and administration.

Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Talk to your doctor or pharmacist if you are not sure.

The recommended dose is 1 white day tablet in the morning and 1 blue-white night capsule in the evening before bedtime; if necessary, another tablet can be administered at noon and one in the early evening. The maximum dose of 3 tablets and 1 capsule should not be exceeded. An interval of at least 4 hours between administrations should be observed. The interval increases to 8 hours in severe renal insufficiency, but only on medical recommendation.

The tablet or capsule should be swallowed with a large glass of water.

The maximum duration of treatment is 4 days.

Precautions.

Before taking HUMAGRIP tablets and capsules, talk to your doctor or pharmacist.

The absence of improvement or worsening of symptoms after 4 days of treatment, the appearance of an allergic reaction, tachycardia, palpitations, arterial hypertension, arrhythmias, nausea or neurological signs require discontinuation of treatment and seeking medical attention.

Paracetamol and its metabolites are excreted mainly in the urine, and therefore, in severe renal insufficiency, the interval between doses should be increased to 8 hours.

If other medicines are also administered, their paracetamol content must be checked to avoid overdose.

In adults and children weighing over 50 kg, the total dose of paracetamol should not exceed 3 g per day.

Special warnings.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

The presence of pseudoephedrine requires avoiding the use of HUMAGRIP during pregnancy. Experimental and clinical studies conducted on several hundred pregnant women have excluded the teratogenic effect of pseudoephedrine. Fetal toxicity is related to the pharmacological action of the molecule and may manifest as fetal tachycardia and hyperactivity.

Consequently, pseudoephedrine can be prescribed during pregnancy only if absolutely necessary and only on medical recommendation. It is contraindicated when there is fetal distress or hypertensive maternal pathology.

HUMAGRIP is contraindicated during breastfeeding, as pseudoephedrine is excreted in breast milk and can cause tachycardia in the infant.

Driving and using machines

Drivers and people operating various machines should be warned that HUMAGRIP may cause drowsiness or slight agitation.

Packaging. Box with a PVC/Al blister containing 12 tablets and 4 capsules.

Page updated on: 25.08.2022